ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements
Trident Lifeline Ltd conducted its 13th Annual General Meeting on September 26, 2026, to approve financial statements, director re-appointment, and managerial remuneration proposals.
Trident Lifeline Limited clarified to the stock exchange that recent share price movements are purely market-driven, confirming no pending undisclosed material information.
Trident Lifeline Limited received an award from PHARMEXCIL for its contribution to India's pharmaceutical exports. This recognition highlights the company's growth in global markets.
Trident Lifeline Limited has scheduled its 13th Annual General Meeting for September 26, 2026. The company concurrently released its Annual Report for the financial year 2025-26.
Trident Lifeline Ltd has revised its Book Closure dates and e-voting Cut-off date for the 13th Annual General Meeting. New Book Closure begins September 20, 2026.
Trident Lifeline Limited allotted 24,000 equity shares upon conversion of warrants at ₹266 per share. This exercise increased the company's paid-up share capital.
Trident Lifeline allotted 24,000 equity shares upon the conversion of 24,000 warrants, aggregating Rs. 0.48 Crore. This allotment changes the company's paid-up equity share capital.
Trident Lifeline Ltd has been selected for the 'Outstanding Contribution to India's Pharmaceutical Exports' award by PHARMEXCIL. The award ceremony is scheduled for September 7, 2026.
Trident Lifeline Limited approved the Board’s Report for FY 2026 and the draft notice for its 13th AGM scheduled for September 26, 2026.
Trident Lifeline Limited announced it was featured in India Pharma Outlook magazine. The feature highlights the company's growth, business strengths, and strategic initiatives.
Trident Lifeline Limited has been selected for the 'Fastest Growing SMEs' award by India SME Forum and Axis Bank in the Top 50 SME Awards - Gujarat.
Trident Lifeline (TLL) achieved ₹129 Cr consolidated revenue in FY26, a 48% increase. Strategy centers on a demand-led manufacturing model and aggressive global registration expansion.
Trident Lifeline Ltd reported revenue from operations of ₹33.7 Cr (+42.8% YoY) and net profit of ₹5 Cr (+61.3% YoY) for Q1 FY27.
Trident Lifeline Ltd scheduled a Board Meeting for July 29, 2026. The meeting will consider the unaudited financial results for the June 30, 2026 quarter.
Trident Lifeline shareholders approved migrating from BSE SME to the Main Board of BSE and NSE. They also confirmed appointing two Independent Directors via postal ballot.
Trident Lifeline shareholders approved the migration from BSE SME platform to the Main Boards of BSE and NSE. The resolution was passed via postal ballot with majority support.
Hardik Desai Family Trust, a promoter group entity, acquired 1,200 shares of Trident Lifeline Ltd via open market. This increases promoter holding marginally to 7.78%.
Trident Lifeline Ltd seeks shareholder approval via postal ballot for appointing two independent directors and migrating from BSE SME to main board. The e-voting period runs from June 16 to July 15, 2026.
Trident Lifeline's board approved two independent director appointments and a migration from SME to main board. The moves strengthen governance and signal a growth phase.
Trident Lifeline Limited's stake in subsidiary Trident Mediquip Limited diluted from 59.17% to 58.84%. The change follows the subsidiary's private placement of shares to other investors.
Shikha Ashish Bafna acquired 3,000 shares of Trident Lifeline Limited via the open market. The non-promoter acquisition increases the holder's total stake to 0.23%.
Hardik Desai Family Trust, a promoter group entity, acquired 9,000 shares of Trident Lifeline Limited via the open market. This increases their stake to 7.15%.
Trident Lifeline achieved record FY26 revenue exceeding ₹100 crore with a 49% standalone revenue growth. The company maintains a hybrid manufacturing model focused on pharmaceutical formulation exports to emerging markets.
Trident Lifeline Ltd reported revenue from operations of ₹75.7 Cr (+52.6% YoY) and net profit of ₹11.4 Cr (+81.0% YoY) for H2 FY26.
Trident Lifeline reported standalone annual total income of ₹106.07 Crore for FY26. The board also appointed DAC & Co. as internal auditors for FY27.
Trident Lifeline Ltd has rescheduled its Board Meeting to Thursday, May 07, 2026. The board will consider and approve the Audited Financial Results for the half-year and year ended March 31, 2026. The trading window for designated persons remains closed until 48 hours after the results are public.
Trident Lifeline Ltd (TLL) confirmed it is not identified as a 'Large Corporate' as of March 31, 2026, under SEBI's debt fund-raising framework. The company's outstanding borrowings stood at ₹16.22 Crore.
Trident Lifeline Ltd has scheduled a Board Meeting on May 5, 2026, to consider and approve audited financial results for the year ended March 31, 2026. The trading window for company shares remains closed until 48 hours after the results are made public.
Trident Lifeline Limited announced that its subsidiary, Trident Mediquip Limited, allotted equity shares to other shareholders via private placement. Consequently, the company's stake in the subsidiary decreased from 59.47% to 59.17%. The transaction was conducted at arm's length to facilitate further allotment of shares to other investors.
Trident Lifeline Limited's stake in its subsidiary, Trident Mediquip Limited, decreased from 59.77% to 59.47% following a private placement of equity shares by the subsidiary to other shareholders. Trident Mediquip Limited reported a turnover of ₹21.29 Crore for FY 2024-25.